Article Details
Retrieved on: 2018-01-27 20:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>In its Series C-1 funding, completed in August 2017, ARMO raised $67 million led by China investor Qiming Ventures, and joined by new China investors Decheng Capital, <b>Sequoia Capital</b>, Quan Capital and RTW Investments. ARMO's lead molecule is AM0010, a pegylated form of Interleukin-10, which ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here